x

Posted 03 August, 2022

Inari Medical, Inc. appointed Andrew Hykes as new CEO

Nasdaq:NARI appointed new Chief Executive Officer Andrew Hykes in a 8-K filed on 03 August, 2022.


  On August 1, 2022, the Board of Directors of the Company approved the appointment of Andrew Hykes as the Chief Executive Officer and President of the Company, succeeding Mr. Hoffman in this role, and as a member of the Board of Directors of the Company, in each case following the Effective Date.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Inari Medical, Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.
Market Cap
N/A
View Company Details
Inari Medical, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 1, 2022, William Hoffman notified Inari Medical, Inc. (the "Company") of his decision to resign as Chief Executive Officer and President of the Company, effective as of December 31, 2022 (the "Effective Date"). Following the effective date of the resignation, Mr. Hoffman will continue in his role as a member of the Company's Board of Directors and will be eligible to receive compensation for such service under the Company's non-employee director compensation program. Mr. Hoffman's outstanding equity awards will continue to vest in accordance with their terms subject to his continued service to the Company as a member of the Board of Directors of the Company. 


On August 1, 2022, the Board of Directors of the Company approved the appointment of Andrew Hykes as the Chief Executive Officer and President of the Company, succeeding Mr. Hoffman in this role, and as a member of the Board of Directors of the Company, in each case following the Effective Date. Mr. Hykes will report directly to the Board of Directors in his new role.


Mr. Hykes, age 49, has served as the Company's Chief Operating Officer since October 2020 and previously served as the Company's Chief Commercial Officer from September 2017 to October 2020. From November 2012 to January 2017, Mr. Hykes was the Vice President of Commercial Operations of Sequent Medical Inc., or Sequent Medical, a private company focused on catheter-based neurovascular therapies that was acquired by Terumo Corporation in July 2016. Prior to this, Mr. Hykes worked for Medtronic PLC, a public medical device company, from August 2002 to October 2012, where he held several positions including: Vice President of Marketing, Vice President of Clinical and Regulatory Affairs and Director of Investor Relations. From 1995 to 2000, Mr. Hykes worked in healthcare banking for ABN AMRO Bank. Mr. Hykes received his B.B.A. from the University of Wisconsin Madison and an M.B.A. from Harvard Business School. 


Additional information regarding Mr. Hykes, including his compensation and any related party transactions, appears in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 14, 2022, under the headings "Executive Compensation" and "Certain Relationships and Related Party Transactions," which information is incorporated herein by reference. 


The Compensation Committee and Board of Directors of the Company will evaluate the compensation of Mr. Hykes as Chief Executive Officer and President of the Company at a later date. As an employee director, Mr. Hykes will not receive any compensation for his service as a member of the Board of Directors of the Company. There are no family relationships between Mr. Hykes and any of the Company's directors or executive officers.